Cohen N, Gilbert R, Wirth A, Casley D, Jerums G
Department of Endocrinology, Austin Hospital, Victoria, Australia.
J Clin Endocrinol Metab. 1996 Apr;81(4):1411-5. doi: 10.1210/jcem.81.4.8636343.
Assessment of mineralocorticoid replacement therapy in Addison's disease relies on clinical features and laboratory measurements, including plasma renin and potassium. Previous studies have questioned the value of measuring the plasma renin concentration (PRC), particularly in the setting of fludrocortisone overreplacement. The aim of this study was to evaluate the usefulness of plasma atrial natriuretic peptide (ANP) measurements as a marker of sodium and volume status in Addison's disease. Fourteen patients with Addison's disease receiving their usual glucocorticoid doses were placed on various doses of fludrocortisone (FC; 0 mg, 0.05 mg, 0.1 mg and 0.2 mg) in random order for four 2-week periods. At the end of each period, blood pressure and clinical symptoms were assessed, and blood was drawn for measurement of PRC and ANP levels. PRC was significantly elevated in patients receiving placebo (54.2 +/- 57.9 ng/mL x h) compared with PRC in those receiving baseline FC (24.7 +/- 42.4 ng/mL x h), 0.1 mg FC (15.2 +/- 25.9 ng/mL x h), and 0.2 mg FC (5.5 +/- 5.7 ng/mL x h). ANP levels were measured by either an extraction method (ANP(ext)) or directly from plasma (ANP(dir)). ANP(dir) was significantly elevated at 0.2 mg FC (87.1 +/- 20.1 pg/mL) compared with baseline (63.3 +/- 8.1 pg/mL), placebo (56.1 +/- 5.5 pg/mL), 0.05 mg FC (60.5 +/- 16.0 pg/mL), and 0.1 mg FC (65.4 +/- 13.7 pg/mL) values. ANP(ext) was elevated in patients receiving 0.2 mg FC (42.7 +/- 41.8 pg/mL) compared with that in patients receiving placebo (7.9 +/- 5.4 pg/mL), 0.05 mg FC (16.2 +/- 11.2 pg/mL), or 0.1 mg FC (19.7 +/- 11.1 pg/mL). Our data suggest that PRC is of value in determining mineralocorticoid underreplacement, whereas ANP is a more sensitive index of FC overreplacement. ANP levels may, therefore, be complementary to PRC in adjustment of mineralocorticoid doses in the upper dose range, where clinical symptoms and signs appear to be of little value.
对艾迪生病患者进行盐皮质激素替代疗法的评估依赖于临床特征和实验室检测,包括血浆肾素和钾水平。既往研究对测定血浆肾素浓度(PRC)的价值提出了质疑,尤其是在氟氢可的松替代过量的情况下。本研究的目的是评估测定血浆心房利钠肽(ANP)作为艾迪生病患者钠和容量状态标志物的实用性。14例接受常规糖皮质激素剂量治疗的艾迪生病患者,按随机顺序在4个为期2周的时间段内接受不同剂量的氟氢可的松(FC;0mg、0.05mg、0.1mg和0.2mg)治疗。在每个时间段结束时,评估血压和临床症状,并采集血样测定PRC和ANP水平。与接受基线FC(24.7±42.4ng/mL·h)、0.1mg FC(15.2±25.9ng/mL·h)和0.2mg FC(5.5±5.7ng/mL·h)的患者相比,接受安慰剂的患者PRC显著升高(54.2±57.9ng/mL·h)。ANP水平通过提取法(ANP(ext))或直接从血浆中测定(ANP(dir))。与基线(63.3±8.1pg/mL)、安慰剂(56.1±5.5pg/mL)、0.05mg FC(60.5±16.0pg/mL)和0.1mg FC(65.4±13.7pg/mL)相比,0.2mg FC时ANP(dir)显著升高(87.1±20.1pg/mL)。与接受安慰剂(7.9±5.4pg/mL)、0.05mg FC(16.2±11.2pg/mL)或0.1mg FC(19.7±11.1pg/mL)的患者相比,接受0.2mg FC的患者ANP(ext)升高(42.7±41.8pg/mL)。我们的数据表明,PRC在确定盐皮质激素替代不足方面有价值,而ANP是FC替代过量更敏感的指标。因此,在调整盐皮质激素高剂量范围时,ANP水平可能是PRC的补充,因为此时临床症状和体征似乎价值不大。